Other large investors have also adjusted their positions in MEDP. Geneos Wealth Management Inc. increased its holdings by an impressive 64.9% in the first quarter, now owning 94 shares valued at $29,000 after acquiring an additional 37 shares. Similarly, Brooklyn Investment Group saw a remarkable 244.8% growth in its holdings, now owning 100 shares worth $30,000 after adding 71 shares. Whittier Trust Co. increased its stake by 47.3%, owning 109 shares valued at $33,000 after purchasing 35 additional shares. Bank Julius Baer & Co. Ltd Zurich entered a new position in Medpace valued at around $60,000 in the first quarter. Lastly, Assetmark Inc. raised its holdings by 24.9%, now owning 216 shares worth $66,000 after buying 43 more shares. Notably, hedge funds and other institutional investors collectively own 77.98% of the company\u2019s stock.<\/p>\n In recent insider news, General Counsel Stephen P. Ewald<\/a> sold 3,000 shares of the firm on July 28th at an average price of $450.00, totaling $1,350,000. Following this transaction, Ewald holds 10,343 shares valued at $4,654,350, marking a 22.48% decrease in his position. This sale was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC website<\/a>. Additionally, Director Cornelius P. Mccarthy III<\/a> sold 1,662 shares on August 19th at an average price of $465.04, amounting to $772,896.48. Post-sale, he owns 10,197 shares valued at $4,742,012.88, reflecting a 14.01% decrease in ownership. Over the past ninety days, insiders have sold 161,266 shares valued at $74,111,427, with insiders currently holding 20.30% of the stock.<\/p>\n Several equities analysts have recently issued reports on Medpace. Barclays raised their target price from $300.00 to $450.00, assigning an \u201cequal weight\u201d rating on July 23rd. Truist Financial also increased their price objective from $298.00 to $436.00, maintaining a \u201chold\u201d rating. Conversely, Rothschild & Co Redburn downgraded Medpace from a \u201cbuy\u201d to a \u201cneutral\u201d rating, raising their target price from $342.00 to $474.00 on September 3rd. UBS Group cut their rating from \u201cneutral\u201d to \u201csell,\u201d adjusting their target price from $300.00 to $305.00 on July 29th. William Blair reaffirmed a \u201cmarket perform\u201d rating on July 23rd. Currently, two analysts rate the stock as a Buy, twelve as Hold, and three as Sell, leading to an average rating of \u201cReduce\u201d and a target price of $422.27 according to MarketBeat.com.<\/p>\n On Monday, shares of MEDP<\/a> opened at $496.79. The company has a fifty-two week low of $250.05 and a high of $506.55. Its fifty-day moving average stands at $464.83, while the two-hundred-day moving average is $361.31. Medpace boasts a market cap of $13.95 billion, a PE ratio of 36.94, a price-to-earnings-growth ratio of 3.13, and a beta of 1.44.<\/p>\n Medpace (NASDAQ:MEDP<\/a> \u2013 Get Free Report<\/a>) recently announced its quarterly earnings on July 21st, reporting $3.10 earnings per share, surpassing analysts\u2019 expectations of $3.00 by $0.10. The firm generated revenue of $603.31 million, exceeding the anticipated $537.70 million. With a net margin of 18.74% and a return on equity of 67.66%, Medpace\u2019s revenue increased by 14.2% compared to the same quarter last year. The company has set its FY 2025 guidance at 13.760-14.53 EPS, with analysts predicting an average of 12.29 earnings per share for the current year.<\/p>\n (Free Report<\/a>)<\/p>\n Medpace Holdings, Inc. specializes in providing outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. Their offerings encompass a wide range of services, including medical department operations, clinical trial management, data-driven feasibility studies, regulatory affairs, patient recruitment, and quality assurance.<\/p>\n Want to see what other hedge funds are holding MEDP?<\/strong> Visit HoldingsChannel.com<\/a> for the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP<\/a> \u2013 Free Report<\/a>).<\/p>\n <\/p>\n <\/p>\n![\"Medpace](\"https:\/\/www.marketbeat.com\/logos\/medpace-holdings-inc-logo-1200x675.jpg\"){kind=logo}
Public Employees Retirement System of Ohio has slightly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP<\/a> \u2013 Free Report<\/a>) by 0.3% during the second quarter, as revealed in its latest filing with the Securities & Exchange Commission. The firm now holds 20,125 shares of Medpace after selling 53 shares during the quarter, with a total value of approximately $6,316,000.<\/p>\nInsider Activity at Medpace<\/h2>\n
Wall Street Analyst Weigh In<\/h2>\n
Medpace Stock Up 1.8%<\/h2>\n
Medpace Company Profile<\/h2>\n
See Also<\/h2>\n
<\/p>\n
\n
\n <\/p>\n